vimarsana.com
Home
Live Updates
Rallybio Announces Preliminary Phase 1 Multiple Ascending Do
Rallybio Announces Preliminary Phase 1 Multiple Ascending Do
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing --
-- Data Supports the Study of RLYB116 as a Differentiated...
Related Keywords
New Haven ,
Connecticut ,
United States ,
Eric Watsky ,
Linkedin ,
Term Development ,
Rallybio Corporation Nasdaq ,
Exchange Commission ,
Program Lead For Rallybio ,
Twitter ,
Rallybio Corporation ,
Term Development Plans ,
Stephen Uden ,
Chief Executive Officer ,
Technology Incubation Program ,
Quarterly Report ,
Markets ,